Kainomyx, Inc.
Kainomyx discovers antimalarial medicines that disrupt the parasite's cytoskeleton, aiming to create treatments with new mechanisms that can help address drug resistance.
What they do
Kainomyx discovers antimalarial medicines that disrupt the parasite's cytoskeleton, aiming to create treatments with new mechanisms that can help address drug resistance.1,2 Its U.S. office is based in Palo Alto, California, with additional drug-discovery work through a collaboration with the Calibr-Skaggs Institute in La Jolla, California.2 The work spans the discovery and development stages, including novel cytoskeletal target validation and assay development, screening for new compounds, high-resolution structures, structure-activity relationships and preclinical optimization of cytoskeletal inhibitors.2
- Palo Alto, CA1,2Headquarters · Research and development
In the field and in development
Partnerships in 1 endemic country
- Dr. Reddy's Laboratories and Aurigene Pharmaceutical Services · non-binding MoU (2024) to develop and commercialize an affordable antimalarial, with Aurigene handling scalable chemistry and Dr. Reddy's handling regulatory and market access4,2
- C-CAMP (Bangalore) · hosts Kainomyx's India subsidiary for its research programs1,2
Who they work with in the United States
- In the atlas
- In the atlas
- In the atlas
Where this comes from
- 1scripps.edu
- 2Confirmed by the organization
- 3biorxiv.org
- 4drugstorenews.com